

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)



(10) International Publication Number
WO 2021/174205 A1

(51) International Patent Classification:

A61K 31/56 (2006.01) A61K 31/575 (2006.01)
A61K 31/568 (2006.01) A61P 25/08 (2006.01)

(21) International Application Number:

PCT/US2021/020308

(22) International Filing Date:

01 March 2021 (01.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/982,717 27 February 2020 (27.02.2020) US

(71) Applicant: **BRII BIOSCIENCES, INC.** [US/US]; We-
Work One City Ctr., Unit 05-130, 110 Corcoran St.,
Durham, North Carolina 27701 (US).

(72) Inventor: **XU, Lianhong**; c/o Brii Biosciences, Inc., We-
Work One City Ctr., Unit 05-130, 110 Corcoran St.,
Durham, North Carolina 27701 (US).

(74) Agent: **YU, Xiaozhen** et al.; Cooley LLP, 1299 Pennsyl-
vania Avenue, NW, Suite 700, Washington, District of Co-
lumbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PRODRUGS OF NEUROACTIVE STEROIDS

(57) Abstract: The present application relates to novel compounds that are prodrugs of brexanolone, ganaxolone and zuranolone, pharmaceutical compositions comprising one or more compounds disclosed herein and salts thereof, and a pharmaceutically acceptable excipient, and use of the compounds disclosed herein and salts thereof for treating diseases or conditions related to GABA_A receptor function, such as major depression disorder (MDD) and postpartum depression (PPD), in mammals and especially in humans.



WO 2021/174205 A1